๐ Insulet $PODD dives 17% โ slashes Omnipod U.S. outlook despite Q2 earnings beat
Insulet got hammered today after cutting its full-year 2026 revenue guidance and lowering U.S. Omnipod sales forecasts โ even though Q2 EPS of $1.66 beat the $1.48 estimate. Type 2 diabetes patient retention challenges are proving stickier than expected. Stock gave back months of gains in one session. Is this a dip worth buying in the diabetes-tech space or the start of a longer slide? Not financial advice.
โก 56 buzzing
461 views
๐ 0 subscribed